Abstract 326P
Background
Exercise is suggested to reduce the recurrence risk in individuals with breast cancer. Evidence regarding relevant physiological mechanisms remains scarce. Here, we examined the association of inflammatory biomarkers with predicted recurrence events.
Methods
The Optitrain randomized controlled trial consisted of 240 patients undergoing chemotherapy for primary breast cancer randomised to interventions entailing biweekly supervised concurrent resistance exercise and high-intensity interval training (RT-HIIT), or concurrent aerobic exercise and HIIT (AT-HIIT), or usual care (UC) between 2013-2016. At baseline and the one-year follow-up, 96 inflammatory protein biomarkers were assessed using the Olink® Proximity Extension Assay Oncology Panel. Group differences were estimated using analysis of covariance adjusted for baseline levels. Recurrence outcomes were obtained from National Swedish registers. Event probabilities were predicted from cox-proportional hazards models adjusted for age, menopause, BMI, tumour characteristics, and taxane treatment. Associations between survival probabilities and inflammatory markers were examined using Pearson’s correlation.
Results
When comparing RT-HIIT and UC, exploratory differences across several C-C-motif chemokine ligands were found (CCL2, CCL3, CCL4, CCL13, CCL20, CCL23). Moreover, DCN, ICOSLG, soluble CD8 and CD4, CX3SL1, CXCL10, CD70, CD83, CSF-1, HGF, NCR1, PD-L2, PIGF, PTN, TNFRSF12A, and TNFRSF21S differed across groups (p<0.2). When examining event probabilities, CD70, soluble CD4, CCL2, CCL3, CCL4, CCL13, CCL20, and CCL23 at the one-year follow-up examinations formed a cluster of a weakly increased risk in recurrence-related events. The strongest associations between event probabilities and biomarkers of inflammation were recorded for distant recurrence-free interval events.
Conclusions
Explorative analyses assessing the interplay of systemic inflammation, exercise, and predicted event probabilities suggested a cluster of inflammatory biomarkers affected by exercise and positively correlated with recurrence-related predicted event probabilities.
Clinical trial identification
NCT02522260, August 13, 2015.
Editorial acknowledgement
Legal entity responsible for the study
Region Stockholm.
Funding
1. The Swedish Cancer and Traffic Accident Foundation (CTRF) (grant number F-C-001225) 2. Swedish Cancer Foundation (grant number 130452) 3. Radiumhemmet Research foundation (grant number 131242) 4. Karolinska Institutet School of Caring Sciences (grant number 04960/2012).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
354P - Synergistic preclinical efficacy through combination of the CDK4 and CDK2 selective inhibitors, PF-07220060 and PF-07104091, respectively, in HR+ HER2- breast cancer
Presenter: Lars Anders
Session: Poster session 14
355P - EVERolimus effectiveness after proGREssion on CDK4/6 inhibitors for ENdocrine receptor-positive/HER2-negative, advanced breast cancer: EVERGREEN quasi-experimental study
Presenter: Soraia Lobo-Martins
Session: Poster session 14
356P - Real-world effectiveness in subgroups of palbociclib + endocrine therapy in HR+/HER2- ABC patients: Interim results of the PERFORM study
Presenter: Georg Pfeiler
Session: Poster session 14
358P - Everolimus or ribociclib in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and circulating tumor cells: Results from DETECT IVa
Presenter: Tanja Fehm
Session: Poster session 14
359P - Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study
Presenter: Takahiro Nakayama
Session: Poster session 14
360P - Identification of circulating immune factors as predictive biomarkers of CDK4/6i treatment efficacy in advanced breast cancer
Presenter: Sara Cabrero-de las Heras
Session: Poster session 14
361P - PALVEN: A phase Ib study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
Presenter: Christine Muttiah
Session: Poster session 14
362P - Dose reductions due to treatment-related side effects and survival outcomes in breast cancer patients treated with CDK4/6 Inhibitors
Presenter: Pinar Kubilay Tolunay
Session: Poster session 14
363P - Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer
Presenter: Sanne Buijs
Session: Poster session 14